Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers.

NCT04260529 is registered in ClinicalTrials.gov with Cytovation AS as lead sponsor.

NCT NCT04260529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04260529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers.
Lead sponsor
Cytovation AS
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2020
Completion date
July 5, 2024
Enrollment
60 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor malignancy